Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

HIV Infection

Free Subscription 09.03.2026 3 AIDS 1 AIDS Res Hum Retroviruses 1 Antimicrob Agents Chemother 1 BMC Cancer 1 BMC Pediatr 4 Clin Infect Dis 3 HIV Med 1 J Acquir Immune Defic Syndr 1 J Immunol 2 J Infect Dis 1 J Virol 1 Lancet 1 MMWR Morb Mortal Wkly Rep 1 Pediatrics 6 PLoS One 1 PLoS Pathog 2 Science 1 Vaccine 1 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. ANESTEN B, Zetterberg H, Nilsson S, Fuchs D, et al
   Comprehensive study of cerebrospinal fluid beta2-microglobulin, a marker of central nervous system immune activation in individuals with HIV.
   AIDS. 2026 Mar 6. doi: 10.1097/QAD.0000000000004482.
   PubMed         Abstract available
   
   
2. HENDRIX CW, Hillier SL, Bekker LG, Badal-Faesen S, et al
   Islatravir distribution in plasma, peripheral blood mononuclear cells, and mucosal tissues after monthly oral dosing.
   AIDS. 2026 Mar 6. doi: 10.1097/QAD.0000000000004477.
   PubMed         Abstract available
   
   
3. NYEIN PP, Donoghoe MW, Eriobu N, Uche B, et al
   Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial.
   AIDS. 2026 Mar 3. doi: 10.1097/QAD.0000000000004476.
   PubMed         Abstract available
   
   

   
   AIDS Res Hum Retroviruses

4. WANG Y, Yu Y, Wang P, Yang X, et al
   Analysis of HIV Status and Related Risk Factors Among Men Who Have Sex with Men from 2019 to 2021 in Qingdao, China: A Cross-Sectional Study.
   AIDS Res Hum Retroviruses. 2026;42:117-125.
   PubMed         Abstract available
   
   

   
   Antimicrob Agents Chemother

5. MARANCHICK NF, Martyn-Dickens C, Enimil A, Yang H, et al
   Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV.
   Antimicrob Agents Chemother. 2026 Mar 2:e0090925. doi: 10.1128/aac.00909.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. ABERA GB, Alemayehu M, Sori DA, Ali R, et al
   Time to death and its determinants among cervical cancer patients in Tigray, Ethiopia: a retrospective follow up study.
   BMC Cancer. 2026 Mar 2. doi: 10.1186/s12885-026-15712.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

7. GIZAW T, Kebede A, Hunduma HF, Serba HA, et al
   Time to treatment failure and its predictors among children attending antiretroviral therapy in Jimma, southwest Ethiopia: a retrospective cohort study.
   BMC Pediatr. 2026 Mar 5. doi: 10.1186/s12887-026-06674.
   PubMed        
   
   

   
   Clin Infect Dis

8. YANG E, Van Brantegem P, Peloquin CA, Brooks MB, et al
   Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis.
   Clin Infect Dis. 2026 Mar 6:ciag141. doi: 10.1093.
   PubMed         Abstract available
   
   
9. DORWARD J, Masombuka X, Lewis L, Pastellides C, et al
   Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-Identified Data From South Africa.
   Clin Infect Dis. 2026 Mar 4:ciag155. doi: 10.1093.
   PubMed         Abstract available
   
   
10. LOVEDAY M, Clarence E, Brust JCM, Waitt C, et al
    Responding appropriately to safety signals in infants exposed to the 6-month BDLLfx/BDLCfz regimen in utero.
    Clin Infect Dis. 2026 Mar 3:ciag143. doi: 10.1093.
    PubMed        
    
    
11. NELLORE A, Goepfert P, Tan CS, Bajema K, et al
    IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19, Influenza, and RSV infections in immunocompromised patients.
    Clin Infect Dis. 2026 Mar 2:ciag114. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    HIV Med

12. FLAVELL CA, Crowe M, Kenchington P, Jones A, et al
    Disability and frailty in people living with Human Immunodeficiency Virus in regional Australia: A cross-sectional study with a measurement property assessment of the HIV Disability Questionnaire.
    HIV Med. 2026 Mar 5. doi: 10.1111/hiv.70212.
    PubMed         Abstract available
    
    
13. WEIS N, Chirwa M, Sabin CA
    Recognizing international Women's day 2026.
    HIV Med. 2026 Mar 3. doi: 10.1111/hiv.70213.
    PubMed        
    
    
14. ZHANG L, Chen L, Tang J, Liu X, et al
    Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system.
    HIV Med. 2026 Mar 3. doi: 10.1111/hiv.70205.
    PubMed         Abstract available
    
    

    
    J Acquir Immune Defic Syndr

15. INMAN EM, Ramsammy CW, Kalegina A, Robbins RN, et al
    Effects of HIV and adverse childhood experiences on neurocognition.
    J Acquir Immune Defic Syndr. 2026 Mar 3. doi: 10.1097/QAI.0000000000003858.
    PubMed         Abstract available
    
    

    
    J Immunol

16. HINER C, Mueller A, Garforth S, Santos Bravo M, et al
    HIV- and cytomegalovirus-specific human memory CD8+ T cells are activated and expanded independent of co-stimulatory signaling by T-cell receptor-specific immunotherapeutics.
    J Immunol. 2026;215:vkaf329.
    PubMed         Abstract available
    
    

    
    J Infect Dis

17. TEIXEIRA AR, Caskey M
    What's Hot in HIV in 2025-A Basic and Translational Science Review from IDWeek 2025.
    J Infect Dis. 2026 Mar 3:jiag135. doi: 10.1093.
    PubMed         Abstract available
    
    
18. MAKORI TO, Gicheru ET, Mburu MW, Sada MS, et al
    Nasopharyngeal Microbiome Composition and its Clinical Correlates in Children Hospitalized with Severe Pneumonia in East Africa.
    J Infect Dis. 2026 Mar 3:jiag093. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

19. ATABEY T, Derking R, Newby ML, Bouhuijs JH, et al
    Differential contributions of human oligosaccharyltransferase complexes OST-A and OST-B to HIV-1 envelope glycoprotein glycosylation.
    J Virol. 2026 Mar 4:e0148125. doi: 10.1128/jvi.01481.
    PubMed         Abstract available
    
    

    
    Lancet

20. ORKIN C, Ruane PJ, Hedgcock M, Gaultier C, et al
    Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.
    Lancet. 2026 Feb 25:S0140-6736(26)00307-7. doi: 10.1016/S0140-6736(26)00307.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

21. KRACALIK I, Annambhotla P, McCormick DW, Geller AI, et al
    Kaposi Sarcoma-Associated Herpesvirus Infection and Complications Among Solid Organ Transplant Recipients - United States, January 2021-September 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:99-105.
    PubMed         Abstract available
    
    

    
    Pediatrics

22. LIU Y, Phares CR, Logan P, Weinberg MS, et al
    Tuberculosis Disease and Infection in US-Bound International Adoptees: 2016 to 2023.
    Pediatrics. 2026 Mar 4:e2025073442. doi: 10.1542/peds.2025-073442.
    PubMed         Abstract available
    
    

    
    PLoS One

23. SHOYEMI E, Aghedo OG, Obi C, Uwaoma CPK, et al
    Impact of demographic factors and HIV status on Hepatitis B vaccination adherence and completion rate among high-risk populations in Lagos State, Nigeria.
    PLoS One. 2026;21:e0321434.
    PubMed         Abstract available
    
    
24. ALIA SM, Zoubeidi TL, Ali HI
    Nutrition-related knowledge, attitudes, practice, and mental health status of people living with HIV in Dubai, United Arab Emirates: A cross-sectional descriptive study.
    PLoS One. 2026;21:e0344288.
    PubMed         Abstract available
    
    
25. KASULE J, Tonzel JL, Burns N, Hamby T, et al
    COVID-19 knowledge, attitudes, and practices among people vulnerable to HIV in Uganda: A cross-sectional cohort analysis.
    PLoS One. 2026;21:e0343507.
    PubMed         Abstract available
    
    
26. MPHOTHULO N, Loveday M
    Designing and evaluating the acceptability of a psychosocial and socioeconomic support package for people with drug-resistant tuberculosis in Johannesburg, South Africa.
    PLoS One. 2026;21:e0343154.
    PubMed         Abstract available
    
    
27. MUHENJE O, Olungah CO, Omia DO, Ondondo RO, et al
    Resilient in adversity: Innovative treatment support interventions in facilitating ART adherence among young adults living with HIV in the informal settlements of Kibera, Nairobi.
    PLoS One. 2026;21:e0322823.
    PubMed         Abstract available
    
    
28. DELGADO AJ, Cossman JS, BeLue R
    A comparative analysis of HIV status by sociodemographic and sexual behavior characteristics among men in Bexar county, Texas: An Ending the HIV Epidemic priority county.
    PLoS One. 2026;21:e0333665.
    PubMed         Abstract available
    
    

    
    PLoS Pathog

29. CHEN Y, Klute S, Bansal A, Sparrer KMJ, et al
    HIV-1 Vpr is targeted for degradation by autophagy.
    PLoS Pathog. 2026;22:e1014020.
    PubMed         Abstract available
    
    

    
    Science

30. ANKETELL MJ, Fung E, Liu W, Shinde M, et al
    A unified platform for nucleoside analog synthesis.
    Science. 2026 Mar 5:eaed6880. doi: 10.1126/science.aed6880.
    PubMed         Abstract available
    
    
31. COHEN J
    Community health project slashes new HIV infections.
    Science. 2026;391:971.
    PubMed         Abstract available
    
    

    
    Vaccine

32. RUIZ-PALACIOS GM, Cahn PE, Halperin SA, Wang R, et al
    Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.
    Vaccine. 2026;78:128378.
    PubMed         Abstract available
    
    

    
    Virology

33. HAKIM MS, Widyaningsih SA, Ikram A, Goeijenbier M, et al
    Fundamental concepts of convergent (parallel) evolution in human-pathogenic viruses and their implications for global health.
    Virology. 2026;618:110854.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum